Clinical effectiveness of neuraminidase inhibitors—oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan

Abstract The clinical effectiveness of the newly released neuraminidase inhibitors (NAIs) laninamivir and peramivir has not been sufficiently evaluated in influenza-infected patients in clinical and practical settings. In this study, we analyzed the clinical data of 211 patients infected with influe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2012, Vol.18 (6), p.858-864
Hauptverfasser:	Shobugawa, Yugo, Saito, Reiko, Dapat, Clyde, Dapat, Isolde Caperig, Kondo, Hiroki, Saito, Kousuke, Sato, Isamu, Kawashima, Takashi, Suzuki, Yasushi, Suzuki, Hiroshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiviral Agents - therapeutic use Child Child, Preschool Clinical effectiveness Cyclopentanes - therapeutic use Disease Outbreaks Enzyme Inhibitors - therapeutic use Female Fever alleviation Guanidines - therapeutic use Hematology, Oncology and Palliative Medicine Humans Infectious Diseases Influenza A Virus, H1N1 Subtype - isolation & purification Influenza A Virus, H3N2 Subtype - isolation & purification Influenza virus Influenza, Human - drug therapy Influenza, Human - epidemiology Influenza, Human - virology Japan - epidemiology Male Medical Microbiology Medicine Medicine & Public Health Neuraminidase - antagonists & inhibitors Neuraminidase inhibitors Observational study Original Article Oseltamivir - therapeutic use Treatment Outcome Virology Zanamivir - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract The clinical effectiveness of the newly released neuraminidase inhibitors (NAIs) laninamivir and peramivir has not been sufficiently evaluated in influenza-infected patients in clinical and practical settings. In this study, we analyzed the clinical data of 211 patients infected with influenza A virus subtype H3N2 (A(H3N2)) and 45 patients infected with influenza A virus subtype H1N1pdm (A(H1N1)pdm09) who received the NAIs oseltamivir, zanamivir, laninamivir, or peramivir during the 2010-2011 influenza season. The duration of fever from the first dose of the NAI to fever alleviation to
ISSN:	1341-321X 1437-7780
DOI:	10.1007/s10156-012-0428-1